Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug ...

Sutacimig is an investigational bispecific antibody designed to bind to endogenous factor VIIa and localize it to activated platelets, thereby promoting thrombin and fibrin formation.

Clotting disorders can be treated by infusing patients with clotting proteins they lack, or with drugs that replace the function of these proteins. Gene therapies may soon become another option.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Hemab Therapeutics raised a $157 million Series C ...

$157M Series C adds leading life science investors including Sofinnova Partners, a large long-only global asset management company, a large global sovereign wealth fund, and Avoro Capital Advisors ...

The weekly dosing cohort achieved an estimated 87% reduction in annualized treated bleeding rate (ATBR) Results validate potential as the first prophylactic therapy to address the heavy physical and ...

Copenhagen, Denmark and Boston, US – 22 July 2021 – Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today ...

While hemophilia has soaked up clinical attention and investor dollars for decades, it’s come at the expense of a range of intriguingly named but less well-known blood clotting disorders. That’s where ...

New company will focus on developing bispecific antibodies for rare bleeding disorders Novo Holdings’ early-stage investment and company creation team Novo Seeds has established a new portfolio ...

(MENAFN- pr newswire) hmb-001 recognizes and binds to factor vii (fvii) protein variants associated with moderate/severe fvii deficiency and drives accumulation of endogenous fvii/fviia to normal ...